The role of retinal pigment epithelial senescence and the potential of senotherapeutics in age-related macular degeneration.
Abstract
Age-related macular degeneration (AMD) is a leading cause of visual impairment in the aging population. Evidence showing the presence of cellular senescence in retinal pigment epithelium (RPE) of patients with AMD is growing. Senescent RPE play a pivotal role in its pathogenesis. The senescent RPE suffers from structural and functional alterations and disruption of the surrounding microenvironment due to the development of the senescence-associated secretory phenotype, which contributes to metabolic dysfunctions and inflammatory responses in the retina. Senotherapeutics, including senolytics, senomorphics and others, are novel treatments targeting senescent cells and are promising treatments for AMD. As senotherapeutic targets are being developed, it is promising that the burden of AMD could be decreased.
The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.
Research summary
Senescent retinal pigment epithelial cells contribute to the pathogenesis of age-related macular degeneration, and targeting these cells with senotherapeutics may reduce the burden of the disease. The paper is relevant as it addresses the role of cellular senescence in aging-related diseases and explores potential interventions that target the underlying mechanisms of aging.
Author of this paper? Send a correction.